JAK inhibitors alter NK cell functions and may impair immunosurveillance against lymphomagenesis

摘要

An increased risk of B cell lymphomas in patients with myeloproliferative neoplasm(MPN)treated with Janus kinase(JAK)inhibitors has recently been explored.1–3 In light of contradictory results,it is highly important to assess whether JAK inhibitors might be associated with a higher risk of lymphoma,notably in patients with pre-existing B cell clones that can escape immunosurveillance after exposure to JAK inhibitors.This situation is very similar to what is observed in patients with autoimmune diseases,especially rheumatoid arthritis(RA).B cell clones are present in patients with RA,and dominant BCR clones in the peripheral blood predict the onset of the disease in at-risk individuals.